LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

AZN

81.26

-0.34%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

AZN

81.26

-0.34%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

AZN

81.26

-0.34%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

AZN

81.26

-0.34%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

AZN

81.26

-0.34%↓

Search

Simulations Plus Inc

Chiusa

SettoreSettore sanitario

14.16 0.21

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

13.92

Massimo

14.29

Metriche Chiave

By Trading Economics

Entrata

-70M

-67M

Vendite

-2.1M

20M

P/E

Media del settore

48.528

35.664

Rendimento da dividendi

0.48

Margine di Profitto

-330.585

Dipendenti

243

EBITDA

-79M

-74M

Raccomandazioni

By TipRanks

Raccomandazioni

Acquista

Previsioni per 12 mesi

+63.84% upside

Dividendi

By Dow Jones

Rendimento da dividendi

Media del settore

0.48%

3.12%

Utili prossimi

22 ott 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

-66M

285M

Apertura precedente

13.95

Chiusura precedente

14.16

Notizie sul Sentiment di mercato

By Acuity

92%

8%

354 / 371 Classifica in Healthcare

Simulations Plus Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

9 set 2025, 23:37 UTC

Azioni calde

Stocks to Watch: Oracle, Wearable Devices, GameStop

9 set 2025, 20:41 UTC

Utili

Oracle's Backlog Surges With Major Customer Deals in 1Q

9 set 2025, 20:30 UTC

Utili

GameStop 2Q Sales, Profit Rise

9 set 2025, 23:19 UTC

Discorsi di Mercato

ANZ Adds a Further 50 Bps in FOMC Cuts to Outlook -- Market Talk

9 set 2025, 21:35 UTC

Utili

Oracle Stock Soars on Strong AI Backlog. Earnings Were Good Enough. -- Barrons.com

9 set 2025, 21:32 UTC

Utili

Oracle's Backlog Swells With Big Customer Deals -- Update

9 set 2025, 21:02 UTC

Acquisizioni, Fusioni, Takeovers

DHL Adds to Healthcare Logistics Services With Acquisition -- Update

9 set 2025, 20:50 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

9 set 2025, 20:33 UTC

Utili

These Stocks Moved the Most Today: Apple, UnitedHealth, Nebius, Wolfspeed, Tourmaline Bio, Albemarle, Dell, and More -- Barrons.com

9 set 2025, 20:26 UTC

Utili

Oracle Stock Soars on Strong Backlog. Earnings Were Good Enough. -- Barrons.com

9 set 2025, 20:23 UTC

Utili

Oracle Stock Soars on Strong Backlog. Earnings Were Good Enough. -- Barrons.com

9 set 2025, 20:12 UTC

Utili

Oracle Stock Jumps on Mixed Earnings Report -- Barrons.com

9 set 2025, 20:10 UTC

Utili

Oracle Expects Cloud Infrastructure Rev to Grow 77% to $18 B This Fiscal Yr >ORCL

9 set 2025, 20:10 UTC

Utili

Oracle Expects to Sign-Up Several Additional Multi-B-dollar Customers and RPO Is Likely to Exceed Half-A-Trillion Dollars Over Next Few Mos

9 set 2025, 20:09 UTC

Utili

Synopsys Sees 4Q Adj EPS $2.76-Adj EPS $2.80 >SNPS

9 set 2025, 20:09 UTC

Utili

Synopsys Sees 4Q Loss/Shr 16c-Loss 27c >SNPS

9 set 2025, 20:08 UTC

Utili

Oracle 1Q Short-term Deferred Rev Were $12.1 B >ORCL

9 set 2025, 20:08 UTC

Utili

Oracle 1Q Operating Income Was $4.3 B >ORCL

9 set 2025, 20:08 UTC

Utili

Oracle Expects MultiCloud Rev to Grow Substantially Every Qtr for Several Years >ORCL

9 set 2025, 20:08 UTC

Utili

Synopsys Sees 4Q Rev $2.23B-$2.26B >SNPS

9 set 2025, 20:07 UTC

Utili

Oracle Total Remaining Performance Obligations Up to $455 B >ORCL

9 set 2025, 20:06 UTC

Utili

Oracle 1Q Software Revenue $5.72B >ORCL

9 set 2025, 20:06 UTC

Utili

Synopsys 3Q Adj EPS $3.39 >SNPS

9 set 2025, 20:06 UTC

Utili

Oracle 1Q Cloud Revenue $7.19B >ORCL

9 set 2025, 20:05 UTC

Utili

Oracle 1Q Rev $14.93B >ORCL

9 set 2025, 20:05 UTC

Utili

Oracle 1Q EPS $1.01 >ORCL

9 set 2025, 20:05 UTC

Utili

Synopsys 3Q EPS $1.50 >SNPS

9 set 2025, 20:05 UTC

Utili

Oracle 1Q Services Revenue $1.35B >ORCL

9 set 2025, 20:05 UTC

Utili

Oracle 1Q Adj EPS $1.47 >ORCL

9 set 2025, 20:05 UTC

Utili

Oracle 1Q Hardware Revenue $670M >ORCL

Confronto tra pari

Modifica del prezzo

Simulations Plus Inc Previsione

Obiettivo di Prezzo

By TipRanks

63.84% in crescita

Previsioni per 12 mesi

Media 23.2 USD  63.84%

Alto 31 USD

Basso 15 USD

Basato su 7 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Simulations Plus Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

7 ratings

4

Acquista

3

Mantieni

0

Vendi

Sentiment

By Acuity

354 / 371 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Prove ribassiste molto forti

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Simulations Plus Inc

Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through Software and Services segments. It also offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. In addition, the company provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, and OBESITYsym products. Further, it offers Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as MonolixSuite products for modeling and simulation that allows for population analyses, rapid clinical trial data analyses, and regulatory submissions. Additionally, the company provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions; and early drug discovery services. Furthermore, it offers creative and insightful consulting services to support its quantitative systems pharmacology and other modeling systems. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California.
help-icon Live chat